AzTrials
AzTrials

TraumaPhase 4NCT01189773

Combined Analgesia to Control Pain in Children Seen in Emergency Department (ED) for a Trauma of a Limb

A Phase 4 study testing ibuprofen and codeine in people with Trauma, run by St. Justine's Hospital at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Prospective study to evaluate the additive value of codeine on ibuprofen in the management of pediatric patient with a trauma of a limb. Read more about this study

Who is it for?
Ages 6 to 18 years
Conditions the study is for
Trauma
What is being tested?
ibuprofen and codeine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
200 participants
Where
1 siteCanada
Study dates
Feb 2008to Oct 2009
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • 6 to 18 years
  • VAS > 3/10
  • Recent trauma (previous 24 hours)

Who cannot join

  • Allergy
  • Asthma exacerbation
  • Critical state
  • Physical abuse
  • Severe developmental delay
  • Recent analgesia (previous 6 hours)
  • Significant other trauma

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • CHU Ste-Justine

    Montreal, Quebec, H3T1C5

Other trials in Canada

About this study

Official title: Efficacy and Security of Combined Analgesia (Opioid and Anti-inflammatory Agent) to Control Pain in Children Seen in the Emergency Department for a Trauma of a Limb

Prospective study to evaluate the additive value of codeine on ibuprofen in the management of pediatric patient with a trauma of a limb.

Read the detailed description

Children's pain in Emergency Departments (ED) is poorly managed even though pain is one of the main symptoms of children consulting to the ED (Alexander et al., 2003; O'Donnell et al., 2002). Literature has repeatedly demonstrated the provision of analgesia to be suboptimal in the pediatric population in general. Friedland \& Kulick (1994) reviewed medical records of 99 children with acute fractures assumed to be painful and found that only 53% received analgesia. Southall et al. (1993) showed that of 181 invasive procedures performed on children receiving intensive care, only 50 (28%) received additional analgesia or sedation and during 36 of these procedures the child grimaced or cried (In Maurice et al., 2002). Pain management practices by nurses and doctors in the emergency department (ED) are poor. Selbst \& Clark (1990) noted that children (< 19 years) presenting with painful conditions in ED were much less likely to receive pain medications than adults (p = .001). Moreover, children were also less likely than adults to receive analgesics at discharge (p < .001). The authors concluded by mentioning that pediatricians and emergency physicians are reluctant to use analgesics for children in pain and needed additional education about management of acute pain. Recently, Brown et al. (2003) obtained similar results in a comparative chart review of adults and children presenting to the ED with a diagnostic of fracture. According to their results, children were least likely to receive any analgesics especially opioids. Compared with adults, a lower proportion (54%) of children (< 15 years) received an opioid (p < .001).

Moreover, results of the PAMPER study (Le May et al., 2005; Le May et al., 2007) revealed that on 150 children who presented themselves in ED for either a fracture, a severe sprain, a burn, an acute abdomen or deep lacerations, nurses and physicians only documented pain on 58% (87/150) of these children, even though these diagnoses are known to generate moderate to severe pain (> 4/10). Treatment of children presenting to the ED with a simple fracture is also poorly managed. Results from the same study showed that only 4 children out of 28 (14%) who presented to the ED with a simple fracture received an analgesic.

Efficacy of several medications has been verified to relieve pain of limb injuries in children consulting to the ED. Results of those studies show that ibuprofen was effective to relieve pain. But, most of these studies had a small sample size which affects their power to generalize their results (Koller et al., 2007; Tanabe et al. 2002). Only the RCT performed by Clark et al. (2007) demonstrated that ibuprofen (10 mg/kg) was more effective, at 60-minute post-administration, than both acetaminophen 15 mg/kg) and codeine (1 mg/kg) alone, to relieve children's pain following a musculoskeletal trauma. This trial had a total sample of 300 patients under 18-year with 100 patients per group. Nevertheless, only 52% of the group of children who received ibuprofen considered that their pain was well managed. On the other hand, it is important to specify that we are aware that codeine is pro-drug and necessitates the co-enzyme 2D6 of the CYP 450 to release morphine the analgesic component. Close to 12% of the Caucasian population do not have this co-enzyme, so codeine is not effective to relieve their pain (Williams et al., 2002). Nevertheless, since it is not part of the emergency physicians' practices at our ED to prescribe an opioid for a limb trauma, we needed evidence-based data to prove that a combination of medication would help decrease pain intensity. Further, this study is the first done at our ED using a combination of analgesics implying an opioid, so we needed to start with a weaker and safer opioid such as codeine.

Kennedy (2004) and Mehlisc (2002) propose the use of a combination of analgesics (opioid and non-steroidal inflammatory drug-NSAID) to better relieve children's pain generated by a musculoskeletal trauma. Their rationale is based on the potential of the NSAID to block pain impulses peripherically and decrease edema and the potential for the opioid to block pain at the level of the nervous central system. Finally, very few studies verified the efficacy of a combination of analgesics to relieve the pain generated by a limb trauma. An exhausted review of the literature did not retrieve any study comparing the efficacy of a combination of codeine and ibuprofen with ibuprofen alone to relieve musculoskeletal pain of children consulting to the ED.

Design: Randomized controlled trial (double blind) with the experimental group receiving codeine + ibuprofen and the control group receiving ibuprofen + placebo. Single site study.

Instruments :Pain will be measured with a Verbal Analogue Scale (VAS). The VAS is a sliding scale divided from 0 mm (absence of pain) to 100 mm (worst pain experienced). The VAS was used in several clinical trials with children and is considered valid for children over 6 years (Clark et al., 2007; Giannoni et al., 2002; Warnock \& Lander, 1998; Elhakim et al., 2003; Tyler et al., 1993).

A checklist will be used to evaluate the incidence of common side effects that might be experienced following the administration of an opioid.

Sample: Randomized sample of 200 children presenting to the ED with an injured limb.

Sample size calculation: The sample size was estimated according to the minimal difference required on the VAS for a significant clinical value. A difference of 15 mm with a standard deviation of 25 mm will be considered clinically significant (Clark et al., 2007). Since we have two groups and four different measuring times, we chose an alpha of 0,01 (bilateral). A sample of 67 children in both experimental and control groups was considered sufficient to detect a difference of 15 mm between each group, with a power of 80%. Our final sample size will be 100 children per group considering a dropping rate of 40%. Since Ste-Justine's ED handles close to 5000 cases of limb trauma per year, it is reasonable to estimate that we will be able to recruit 200 patients over a period of 12 months during the day and evening shifts and on week days only.

Inclusion criteria: 1) 6 to 18 y.o., 2) pain intensity > 30 mm, 3) understand, read and/or speak French or English, 4) injury within the last 24 hrs, 5) trauma to a limb without significant angulation (< 30 degrees).

Exclusion criteria: 1) allergies to opioids, ibuprofen and food coloring, 2) children suffering from asthma, 3) children presenting in a critical state, 4) social and physical abuse cases, 5) children with cognitive deficits (autism), 6) children with multiple traumas, 7) children suffering from chronic pain, 8) Children who received an analgesic within the past six hours.

Setting: The ED of Ste. Justine's University Health Centre in Montreal.

Interventions and double blind procedure: The randomized sequence will be generated by a computer program managed by a pharmacist independent of the study. Children allocated to the experimental group will receive a syrup of codeine and chewable tablets of ibuprofen. The children in the control group will receive a syrup containing a placebo and chewable tablets of ibuprofen. Pain will be measured at triage (before medication administration)-T1, at 60 minutes post-administration-T2, at 90 minutes-T3, and at 120 minutes-T4. Side effects and vital signs including saturation will be measured by the research nurse at each measuring time of the study. For security purposes, a standardized protocol will be elaborated if ever a child presents severe sedation, respiratory depression, nausea/vomiting following the administration of the medication.

Data collection and representativeness of the sample: Research nurses associated with this project will collect data from 12h00 to 20h00 on week days with a possibility of collecting data one week end per month during the same period of time. Children presenting after 10h00 in the ED will be considered for the study. Each recruited participant will be registered on a log sheet (screening log) where all the required information will be registered and the patient will receive a code for confidential purposes. Also, patients refusing to participate or patients presenting outside of the hours allocated for data collection will be registered in a different log (Log RMO- Refusal, Missed, Other) where we will register the chart number, the name of the patient, sex, age, date of visit, reason for consultation and reason why the patient refused or missed.

Statistical analyses: Descriptive statistics will be presented on sociodemographic variables for each group. A covariant model with repeated measures will be used to verify the variation of pain intensity among the groups and over the times of the study. The model will include a Time variable (T-1 to T-4), a Group variable (experimental and control), initial pain intensity at triage (T-1), presence of parents, and use of non-pharmacological methods. Comparisons will be done with an alpha of 0,01. Incidence of side effects among the groups will be compared using chi-squared tests. Finally, intention to treat analyses will be performed on participants randomized, who received the medication, and left the study afterwards.

The following outcomes will be used to measure the achievement of the objectives:

Main outcomes: Pain intensity at 60 min (T-2) and 90 min. (T-3) following administration of the medication compared to pain intensity at triage (T-1).

Secondary outcomes: Incidence of side effects at 60, 90 and 120 min. (T-4) following medication administration.

Conditions
Trauma
Being tested
ibuprofen and codeine
Keywords
pain control, limb trauma
Medical subject headings
Wounds and Injuries, Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ibuprofen and codeineDrug

    Also called advil, motrin

    ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)

Study groups in NCT01189773
Study groupRoleWhat they receive
1ExperimentalIbuprofen given orally (10 mg/kg, max = 600 mg) and codeine given orally (1 mg/kg, max = 60 mg).
Receives: Drug: ibuprofen and codeine
2Placebo comparatorIbuprofen given orally (10 mg/kg, max = 600 mg) and placebo given orally ( identical in taste color to codeine preparation).
Receives: Drug: ibuprofen and codeine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. pain level on Verbal Analogue Scale (VAS) 60 minutes post administration of meds

    Measured: 60 minutes

Secondary outcomes (2)
  1. pain level on Verbal Analogue Scale (VAS) 120 minutes post study meds

    Measured: 120 minutes

  2. side-effects of study meds

    Measured: 120 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Aug 2010 (estimated)
  2. Study startFeb 2008
  3. Primary completionOct 2009
  4. Study completionOct 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01189773
Sponsor's protocol ID
2633
Status last verified
May 2010
First submitted
11 May 2010
Last updated
27 Aug 2010
Results posted
No
Data monitoring committee
No

Publications

  • Jones P, Lamdin R, Dalziel SR. Oral non-steroidal anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury. Cochrane Database Syst Rev. 2020 Aug 12;8(8):CD007789. doi: 10.1002/14651858.CD007789.pub3.

    PubMed 32797734

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing ibuprofen and codeine in people with Trauma, run by St. Justine's Hospital at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Aug 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

pain level on Verbal Analogue Scale (VAS) 60 minutes post administration of meds (time frame: 60 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01189773, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in